Conte D, Romanelli F, Nordio M, Baldacci M, Isidori A
Int J Clin Pharmacol Ther Toxicol. 1985 Nov;23(11):601-3.
The effects of a drug with hemostatic action, "Vascular Factor" (V.F.), on platelet and vascular arachidonic acid metabolism were evaluated in man to establish the lack of side effects on platelet aggregation. Plasma levels of 6-keto PGF1 alpha and thromboxane B2 were determined by RIA in healthy volunteers undergoing treatment with V.F. Results indicate that basal values obtained in these compounds do not present significant variations following treatment with V.F. On the basis of these results, the possibility of administering this drug in atherosclerotic patients is further confirmed.
一种具有止血作用的药物“血管因子”(V.F.)对人体血小板和血管花生四烯酸代谢的影响进行了评估,以确定其对血小板聚集无副作用。通过放射免疫分析法(RIA)测定了接受V.F.治疗的健康志愿者血浆中6-酮前列环素F1α和血栓素B2的水平。结果表明,这些化合物的基础值在接受V.F.治疗后没有出现显著变化。基于这些结果,进一步证实了在动脉粥样硬化患者中使用这种药物的可能性。